• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Boston Scientific beats The Street in Q1

Boston Scientific beats The Street in Q1

April 27, 2022 By Sean Whooley

Boston ScientificBoston Scientific (NYSE:BSX) shares were up this morning on first-quarter results that topped the consensus forecast.

The Marlborough, Massachusetts–based interventional medtech maker posted profits of $97 million, or 7¢ per share, on sales of just over $3 billion for the three months ended March 31, 2022, for a 70.3% bottom-line slide on sales growth of nearly 10%.

Adjusted to exclude one-time items, earnings per share were 39¢, either slightly beating or coming in even with projections on Wall Street, where analysts were looking for sales of $2.95 billion.

Each of Boston Scientific’s business segments (bar the specialty pharmaceuticals business which the company divested last year) experienced revenue growth, with cardiovascular leading the way at 11.4% growth, followed by medical devices (10.5%) and medsurg (9.1%).

“Our growth this quarter was fueled by strong execution from our global team, our innovative portfolio and improved procedure volume,” Boston Scientific Chair and CEO Mike Mahoney said in a news release. “We are pleased with our first-quarter performance and outlook for the full year, despite the impact of macroeconomic headwinds, and we look forward to bringing meaningful innovation to customers and the patients we serve together.”

Boston Scientific said it now expects to log adjusted EPS of between $1.74 and $1.79 raising the low end of that projection from the previously projected $1.73. The company expects revenue growth for the full year to range between 7% and 9%.

“This is an undeniably strong — and quite frankly, much stronger than we expected — quarter from BSX that does give us better line of sight into the still-strong underlying fundamentals, as we continue to believe BSX possesses one of the best product portfolios tied to the highest growth end-markets within large-cap medtech,” SVB Securities analysts said in a report.

“That said, we do remain on the sidelines for now as we watch to see how various market dynamics play out, not only around COVID and ongoing labor shortages but also — and probably most importantly — a competitive launch for [the Watchman stroke prevention device] and successful execution on upcoming new product launches,” said Danielle Antalffy, Priya Sachdeva, Erin S. Fahey, and Ryan Barocas at SVB Securities.

BSX shares were up more than 1% to $43.26 apiece during morning trading today. MassDevice’s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was down slightly.

Filed Under: Business/Financial News, Cardiovascular, Featured, MassDevice Earnings Roundup, News Well, Wall Street Beat Tagged With: Boston Scientific

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy